Evidence mapPaperPMID 37737201Full record

ArticleJournal of translational medicine2023

Hypoxia-induced AFAP1L1 regulates pathological neovascularization via the YAP-DLL4-NOTCH axis.

Jun-Song Ren, Wen Bai, Jing-Juan Ding, Hui-Min Ge, Su-Yu Wang, Xi Chen, Qin Jiang

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MultiZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jun-Song Ren *Department of Ophthalmology, The Affiliated Eye Hospital, Nanjing Medical University, #138 Han-ZhongRoad, Nanjing, 210000, China.
Wen Bai *Department of Ophthalmology, The Affiliated Eye Hospital, Nanjing Medical University, #138 Han-ZhongRoad, Nanjing, 210000, China.
Jing-Juan Ding *Department of Ophthalmology, Xuzhou Central Hospital, Xuzhou, 221000, China.
Hui-Min GeDepartment of Ophthalmology, The Affiliated Eye Hospital, Nanjing Medical University, #138 Han-ZhongRoad, Nanjing, 210000, China.
Su-Yu WangDepartment of Ophthalmology, The Affiliated Eye Hospital, Nanjing Medical University, #138 Han-ZhongRoad, Nanjing, 210000, China.
Xi ChenDepartment of Ophthalmology, The Affiliated Eye Hospital, Nanjing Medical University, #138 Han-ZhongRoad, Nanjing, 210000, China.
Qin JiangDepartment of Ophthalmology, The Affiliated Eye Hospital, Nanjing Medical University, #138 Han-ZhongRoad, Nanjing, 210000, China. jqin710@vip.sina.com.ORCID http://orcid.org/0000-0001-9154-8917
Second Affiliated Hospital of Nanjing Medical University · CNNanjing Medical University · CNNorthern Jiangsu People's Hospital · CNXuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPathological neovascularization plays a pivotal role in the onset and progression of tumors and neovascular eye diseases. Despite notable advancements in the development of anti-angiogenic medications that target vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), the occurrence of adverse reactions and drug resistance has somewhat impeded the widespread application of these drugs. Therefore, additional investigations are warranted to explore alternative therapeutic targets. In recent years, owing to the swift advancement of high-throughput sequencing technology, pan-cancer analysis and single-cell sequencing analysis have emerged as pivotal methodologies and focal areas within the domain of omics research, which is of great significance for us to find potential targets related to the regulation of pathological neovascularization.

methodsPan-cancer analysis and scRNA-seq data analysis were employed to forecast the association between Actin filament-associated protein 1 like 1 (AFAP1L1) and the development of tumors and endothelial cells. Tumor xenograft model and ocular pathological neovascularization model were constructed as well as Isolectin B4 (IsoB4) staining and immunofluorescence staining were used to assess the effects of AFAP1L1 on the progression of neoplasms and neovascular eye diseases in vivo. Transwell assay, wound scratch assay, tube forming assay, three-dimensional germination assay, and rhodamine-phalloidin staining were used to evaluate the impact of AFAP1L1 on human umbilical vein endothelial cells (HUVECs) function in vitro; Dual luciferase reporting, qRT-PCR and western blot were used to investigate the upstream and downstream mechanisms of pathological neovascularization mediated by AFAP1L1.

resultsOur investigation revealed that AFAP1L1 plays a crucial role in promoting the development of various tumors and demonstrates a strong correlation with endothelial cells. Targeted suppression of AFAP1L1 specifically in endothelial cells in vivo proves effective in inhibiting tumor formation and ocular pathological neovascularization. Mechanistically, AFAP1L1 functions as a hypoxia-related regulatory protein that can be activated by HIF-1α. In vitro experiments demonstrated that reducing AFAP1L1 levels can reverse hypoxia-induced excessive angiogenic capacity in HUVECs. The principal mechanism of angiogenesis inhibition entails the regulation of tip cell behavior through the YAP-DLL4-NOTCH axis.

conclusionIn conclusion, AFAP1L1, a newly identified hypoxia-related regulatory protein, can be activated by HIF-1α. Inhibiting AFAP1L1 results in the inhibition of angiogenesis by suppressing the germination of endothelial tip cells through the YAP-DLL4-NOTCH axis. This presents a promising therapeutic target to halt the progression of tumors and neovascular eye disease.

Indexed as

Adaptor Proteins, Signal TransducingEndothelial CellsNeovascularization, PathologicAngiogenesis InhibitorsAnimalsCalcium-Binding ProteinsHumansMicrofilament ProteinsSignal TransductionVascular Endothelial Growth Factor AAdaptor Proteins, Signal TransducingAFAP1L1 protein, humanAngiogenesis InhibitorsCalcium-Binding ProteinsDLL4 protein, humanMicrofilament ProteinsVascular Endothelial Growth Factor AAFAP1L1HIF-1αHypoxiaOcular pathologic neovascularizationTumor angiogenesisVascular tip cell

Identifiers

PMID37737201
PMCPMC10515434
OpenAlexW4386944720

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.